Article Information
History
- January 18, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Shijia Zhang, MBI1,2,*,
- Kimberly Tang, BA1,*,
- Guihong Wan, PhD1,2,*,
- Nga Nguyen, MD, MPH1,
- Chenyue Lu, MBI1,2,
- Pearl Ugwu-Dike, BA1,
- Neel Raval, BA1,
- Jayhyun Seo, BA1,
- Nora A. Alexander, BS1,
- Ruple Jairath, BS1,
- Jordan Phillipps, BS1,
- Bonnie W. Leung, BSc1,
- Kathleen Roster, MS1,
- Wenxin Chen, BS1,2,
- Leyre Zubiri, MD, PhD3,
- Genevieve Boland, MD, PhD4,
- Steven T. Chen, MD, MPH1,
- Hensin Tsao, MD, PhD1,
- Shadmehr Demehri, MD, PhD1,5,
- Nicole R. LeBoeuf, MD, MPH6,
- Kerry L. Reynolds, MD3,
- Kun-Hsing Yu, MD, PhD2,
- Alexander Gusev, PhD7,
- Shawn G. Kwatra, MD8,** and
- Yevgeniy R. Semenov, MD, MA1,**,†
- 1Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- 2Department of Biomedical Informatics, Harvard Medical School, Boston, MA
- 3Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- 4Department of Surgery, Massachusetts General Hospital, Boston, MA
- 5Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- 6Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- 7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
- 8Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD
- ↵†Corresponding author:
Yevgeniy R. Semenov, MD, MA, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, 40 Blossom Street, Bartlett Hall 6R, Room 626, Boston, MA 02114, Email: ysemenov{at}mgh.harvard.edu
Posted January 18, 2023.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study
